1. Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis
- Author
-
Ype de Jong, Esmee M. van der Willik, Joris I. Rotmans, Edouard L Fu, Merel van Diepen, Jet Milders, Olaf M. Dekkers, Vera H.W. van der Endt, Roemer J Janse, and Esther De Rooij
- Subjects
medicine.medical_specialty ,kidney replacement therapy ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Internal medicine ,Diabetes mellitus ,medicine ,030212 general & internal medicine ,Renal replacement therapy ,AcademicSubjects/MED00340 ,Transplantation ,SARS-CoV-2 ,business.industry ,Incidence (epidemiology) ,Acute kidney injury ,COVID-19 ,Original Articles ,medicine.disease ,Intensive care unit ,meta-analysis ,Meta-analysis ,acute kidney injury ,Nephrology ,Relative risk ,Kidney replacement therapy ,business ,Kidney disease - Abstract
BackgroundAcute kidney injury (AKI) can affect hospitalized patients with coronavirus disease 2019 (COVID-19), with estimates ranging between 0.5% and 40%. We performed a systematic review and meta-analysis of studies reporting incidence, mortality and risk factors for AKI in hospitalized COVID-19 patients.MethodsWe systematically searched 11 electronic databases until 29 May 2020 for studies in English reporting original data on AKI and kidney replacement therapy (KRT) in hospitalized COVID-19 patients. Incidences of AKI and KRT and risk ratios for mortality associated with AKI were pooled using generalized linear mixed and random-effects models. Potential risk factors for AKI were assessed using meta-regression. Incidences were stratified by geographic location and disease severity.ResultsA total of 3042 articles were identified, of which 142 studies were included, with 49 048 hospitalized COVID-19 patients including 5152 AKI events. The risk of bias of included studies was generally low. The pooled incidence of AKI was 28.6% [95% confidence interval (CI) 19.8–39.5] among hospitalized COVID-19 patients from the USA and Europe (20 studies) and 5.5% (95% CI 4.1–7.4) among patients from China (62 studies), whereas the pooled incidence of KRT was 7.7% (95% CI 5.1–11.4; 18 studies) and 2.2% (95% CI 1.5–3.3; 52 studies), respectively. Among patients admitted to the intensive care unit, the incidence of KRT was 20.6% (95% CI 15.7–26.7; 38 studies). Meta-regression analyses showed that age, male sex, cardiovascular disease, diabetes mellitus, hypertension and chronic kidney disease were associated with the occurrence of AKI; in itself, AKI was associated with an increased risk of mortality, with a pooled risk ratio of 4.6 (95% CI 3.3–6.5).ConclusionsAKI and KRT are common events in hospitalized COVID-19 patients, with estimates varying across geographic locations. Additional studies are needed to better understand the underlying mechanisms and optimal treatment of AKI in these patients.
- Published
- 2020